Req. No. 8538 Page 1 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
STATE OF OKLAHOMA
2nd Session of the 59th Legislature (2024)
HOUSE BILL 3567 By: Manger
AS INTRODUCED
An Act relating to controlled dangerous drugs;
amending 63 O.S. 2021, Section s 2-101, as last
amended by Section 1, C hapter 375, O.S.L. 2023, 2-
305, as amended by Section 2, Chapter 176, O.S.L.
2023, 2-309, as amended by Section 2, Chapter 304,
O.S.L. 2023 and 2-406, as amended by Section 2,
Chapter 235, O.S.L. 2023 (63 O.S. Supp. 2023,
Sections 2-101, 2-305, 2-309 and 2-406), which relate
to the Uniform Controlled Dangerous Substances Act;
adding and alphabetizing definitions; providing
exception to written order requirement; deeming
written order as final under certain cir cumstances;
directing registrants subject to administrative
action to maintain registration; authorizing the
utilization of electronic prescriptions under certain
circumstances; requiring practitioners to purchase
official prescription forms; providing r estrictions
on use of official prescription forms; modifying
scope of certain prohibited act; repealing
63 O.S. 2021, Sections 2-101, as last amended by
Section 10, Chapter 91, O.S.L. 2019, Section 1,
Chapter 235, O.S.L. 2023, Section 1, Chapter 304,
O.S.L. 2023, 2-305, as last amended by Section 4,
Chapter 375, O.S.L. 2023, 2-309 as last amended by
Section 1, Chapter 333, O.S.L. 2021 and 2-406, as
last amended by Section 7, Chapter 375, O.S.L. 2023
(63 O.S. Supp. 2023, Section s 2-101, 2-305, 2-309 and
2-406), which relate to the Uniform Controlled
Dangerous Substance Act; and providing an effective
date.
Req. No. 8538 Page 2 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -101, as
last amended by Section 1, Chapter 375, O.S.L. 2023 (63 O.S. Supp.
2023, Section 2-101), is amended to read as follows:
Section 2-101. As used in the Uniform Controlled Dangerous
Substances Act:
1. "Acute pain" means pain, whether resulting from disease,
accidental or intentional trauma or other cause, that the
practitioner reasonably expects to last only a short period of time.
Acute pain does not include chronic pain, pain being treated as part
of cancer care, hospice or other end-of-life care, or pain being
treated as part of palliative care;
2. "Administer" means the direct application of a controlled
dangerous substance, whether by injection, inhalation, ingestion or
any other means, to the body of a patient, animal or research
subject by:
a. a practitioner (or, in the presence of the
practitioner, by the authorized agent of the
practitioner), or
b. the patient or research subject at the direction and
in the presence of the practitioner;
2. 3. "Agent" means a peace officer appointed by and who acts
on behalf of the Director of the Oklahoma State Bureau of Narcotics
and Dangerous Drugs Control or an authorized person who acts on
Req. No. 8538 Page 3 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
behalf of or at the direction of a person who manufactures,
distributes, dispenses, prescribes, administers or uses for
scientific purposes controlled dangerous substances but does not
include a common or contract carrier, public warehouser or employee
thereof, or a person required to register under the Uniform
Controlled Dangerous Substances Act;
4. "Anhydrous ammonia" means any substance that exhibits
cryogenic evaporative behavior and tests positive for ammonia;
5. "Beneficial owner" means the natural person or natural
persons who ultimately own or control a legal entity, as well as the
natural person or natural persons on whose behalf a busi ness is
conducted including those natural persons who exercise ultimate
effective control over a legal entity or arrangement ;
3. 6. "Board" means the Advisory Board to the Director of the
Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
4. 7. "Bureau" means the Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control;
8. "Chronic pain" means pain that persists beyond the usual
course of an acute disease or healing of an injury. Chronic pain
may or may not be associated with an acute or chronic pathologic
process that causes continuous or intermittent pain over months or
years;
5. 9. "Coca leaves" includes cocaine and any compound,
manufacture, salt, derivative, mixture or preparation of coca
Req. No. 8538 Page 4 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
leaves, except derivatives of coca leaves which do not contain
cocaine or ecgonine;
6. 10. "Commissioner" or "Director" means the Director of the
Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
7. 11. "Control" means to add, remove or change the placement
of a drug, substance or immediate precursor under the Uniform
Controlled Dangerous Substances Act;
8. 12. "Controlled dangerous substance" means a drug, substance
or immediate precursor in Schedules I through V of the Uniform
Controlled Dangerous Substances Act or any drug, substance or
immediate precursor listed either temporarily or permanently as a
federally controlled substance. Any conflict between state and
federal law with regard to the particular schedule in which a
substance is listed shall be resolved in favor of state law;
9. 13. "Counterfeit substance" means a controlled substance
which, or the container or labeling of which without authorization,
bears the trademark, trade name or other identifying marks, imprint,
number or device or any likeness thereof of a manufacturer,
distributor or dispenser other than the person who in fact
manufactured, distributed or dispensed the substance;
10. 14. "Deliver" or "delivery" means the actual, constructive
or attempted transfer from one person to another of a controlled
dangerous substance or drug paraphernalia, whether or not there is
an agency relationship;
Req. No. 8538 Page 5 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
11. 15. "Dispense" means to deliver a controlled dangerous
substance to an ultimate user or human research subject by or
pursuant to the lawful order of a practitioner, including the
prescribing, administering, packaging, labeling or compounding
necessary to prepare the substance for such distribution.
"Dispenser" is a practitioner who delivers a controlled dangerous
substance to an ultimate user or human research subject;
12. 16. "Distribute" means to deliver other than by
administering or dispensing a controlled dangerous substance;
13. 17. "Distributor" means a commercial entity engaged in the
distribution or reverse distribution of narcotics and dangerous
drugs and who complies with all regulations promulgated by the
federal Drug Enforcement Administration and the Oklahoma State
Bureau of Narcotics and Dangerous Drugs Control;
14. 18. "Drug" means articles:
a. recognized in the official United States Pharmacopeia,
official Homeopathic Pharmacopoeia of the United
States, or official National Formulary, or any
supplement to any of them,
b. intended for use in the diagnosis, cure, mitigation,
treatment or prevention of disease in man or other
animals,
c. other than food, intended to affect the structure or
any function of the body of man or other animals, and
Req. No. 8538 Page 6 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
d. intended for use as a component of any article
specified in this paragraph;
provided, however, the term drug does not include devices or their
components, parts or accessories;
19. "Drug paraphernalia" means all equipment, products, and
materials of any kind which are used, intended for use, or fashioned
specifically for use in planting, propagating, cultivating, growing,
harvesting, manufacturing, comp ounding, converting, producing,
processing, preparing, testing, analyzing, packaging, repackaging,
storing, containing, concealing, injecting, ingesting, inhaling, or
otherwise introducing into the human body, a controlled dangerous
substance in violation o f the Uniform Controlled Dangerous
Substances Act including, but not limited to:
a. kits used, intended for use, or fashioned specifically
for use in planting, propagating, cultivating, growing
or harvesting of any species of plant which is a
controlled dangerous substance or from which a
controlled dangerous substance can be derived,
b. kits used, intended for use, or fashioned specifically
for use in manufacturing, compounding, converting,
producing, processing, or preparing controlled
dangerous substances ,
c. isomerization devices used, intended for use, or
fashioned specifically for use in increasing the
Req. No. 8538 Page 7 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
potency of any species of plant which is a controlled
dangerous substance,
d. testing equipment used, intended for use, or fashioned
specifically for use in identifying, or in analyzing
the strength, effectiveness, or purity of controlled
dangerous substances,
e. scales and balances used, intended for use, or
fashioned specifically for use in weighing or
measuring controlled dangerous substances,
f. diluents and adulterants, such as quinine
hydrochloride, mannitol, mannite, dextrose and
lactose, used, intended for use, or fashioned
specifically for use in cutting controlled dangerous
substances,
g. separation gins and sifters used, intended for use, or
fashioned specifically for use in removing twigs and
seeds from, or in otherwise cleaning or refining
marijuana,
h. blenders, bowls, containers, spoons, and mixing
devices used, intended for use, or fashioned
specifically for use in compounding controlled
dangerous substances,
i. capsules, balloons, envelopes, and other containers
used, intended for use, or fashioned specifically for
Req. No. 8538 Page 8 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
use in packaging small quantities of controlled
dangerous substances,
j. containers and other objects used, intended for use,
or fashioned specifically for use in parenterally
injecting controlled dangerous substances into the
human body,
k. hypodermic syringes, needles, and other objects used,
intended for use, or fashioned specifically for use in
parenterally injecting controlled dan gerous substances
into the human body except as authorized by Section 2-
1101 of this title,
l. objects used, intended for use, or fashioned
specifically for use in ingesting, inhaling, or
otherwise introducing marijuana, cocaine, hashish, or
hashish oil into the human body, such as:
(1) metal, wooden, acrylic, glass, stone, plastic, or
ceramic pipes with or without screens, permanent
screens, hashish heads, or punctured metal bowls,
(2) water pipes,
(3) carburetion tubes and devices,
(4) smoking and carburetion masks,
(5) roach clips, meaning objects used to hold burning
material, such as a marijuana cigarette, that has
Req. No. 8538 Page 9 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
become too small or too short to be held in the
hand,
(6) miniature cocaine spoons and cocaine vials,
(7) chamber pipes,
(8) carburetor pipes,
(9) electric pipes,
(10) air-driven pipes,
(11) chillums,
(12) bongs, or
(13) ice pipes or chillers,
m. all hidden or novelty pipes, and
n. any pipe that has a tobacco bowl or chamber of less
than one-half (1/2) inch in diameter in which there is
any detectable residue of any controlled dangerous
substance as defined in this section or any other
substances not legal for possession or use;
provided, however, the term drug paraphernalia shall not include
separation gins intended for use in preparing tea or spice, clamps
used for constructing electrical equipment, water pipes designed for
ornamentation in which no detectable amount of an illegal substance
is found or pipes designed and used solely for smoking tobacco,
traditional pipes of an American Indian tribal religious ceremony,
antique pipes that are thirty (30) years of age or older, or drug
Req. No. 8538 Page 10 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
testing strips possessed by a person for purposes of determining the
presence of fentanyl or a fentanyl-related compound;
15. 20. "Drug-dependent person" means a person who is using a
controlled dangerous substance and who is in a state of psychic or
physical dependence, or both, arising from administration of that
controlled dangerous substance on a continuous basis. Drug
dependence is characterized by behavioral and other responses which
include a strong compulsion to take the substance on a continuous
basis in order to experience its psychic effects, or to avoid the
discomfort of its absence;
21. "Harm-reduction services" means programs established to:
a. reduce the spread of infectious diseases r elated to
injection drug use,
b. reduce drug dependency, over dose deaths and associated
complications, and
c. increase safe recovery and disposal of used syr inges
and sharp waste;
22. "Hazardous materials" means materials, whether solid,
liquid or gas, which are toxic to human, animal, aquatic, or plant
life, and the disposal of which materials is controlled by state or
federal guidelines;
16. 23. "Home care agency" means any sole proprietorship,
partnership, association, corporation, or other organization which
administers, offers, or provides home care services, for a fee or
Req. No. 8538 Page 11 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
pursuant to a contract for such services, to clients in their place
of residence;
17. 24. "Home care services" means skilled or personal care
services provided to clients in their place of residence for a fee;
18. 25. "Hospice" means a centrally administered, nonprofit or
for-profit, medically directed, nurse-coordinated program which
provides a continuum of home and inpatient care for the terminally
ill patient and the patient's family. Such term shall also include
a centrally administered, nonprofit or for-profit, medically
directed, nurse-coordinated program if such program is licensed
pursuant to the provisions of the Uniform Controlled Dangerous
Substances Act. A hospice program offers palliative and supportive
care to meet the special needs arising out of the physical,
emotional and spiritual stresses which are experienced during the
final stages of illness and during dying and bereavement. This care
is available twenty-four (24) hours a day, seven (7) days a week,
and is provided on the basis of need, regardless of ability to pay.
"Class A" Hospice refers to Medicare-certified hospices. "Class B"
refers to all other providers of hospice services;
19. 26. "Imitation controlled substance" means a substance that
is not a controlled dangerous substance, which by dosage unit
appearance, color, shape, size, markings or by representations made,
would lead a reasonable person to believe that the substance is a
controlled dangerous substance. In the event the appearance of the
Req. No. 8538 Page 12 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
dosage unit is not reasonably sufficient to establish that the
substance is an imitation controlled substance, the court or
authority concerned should consider, in addition to all oth er
factors, the following factors as related to "representations made"
in determining whether the substance is an imitation controlled
substance:
a. statements made by an owner or by any other person in
control of the substance concerning the nature of the
substance, or its use or effect,
b. statements made to the recipient that the substance
may be resold for inordinate profit,
c. whether the substance is packaged in a manner normally
used for illicit controlled substances,
d. evasive tactics or actions utilized by the owner or
person in control of the substance to avoid detection
by law enforcement authorities,
e. prior convictions, if any, of an owner, or any other
person in control of the object, under state or
federal law related to controlled substances or fraud,
and
f. the proximity of the substances to controlled
dangerous substances;
20. 27. "Immediate precursor" means a substance which the
Director has found to be and by regulation designates as being the
Req. No. 8538 Page 13 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
principal compound commonly used or produced primarily for use, and
which is an immediate chemical intermediary used, or likely to be
used, in the manufacture of a controlled dangerous substance, the
control of which is necessary to prevent, curtail or limit such
manufacture;
28. "Initial prescription" means a prescription issued to a
patient who:
a. has never previously been issued a prescription for
the drug or its pharmaceutical equivalent in the past
year, or
b. requires a prescription for the drug or its
pharmaceutical equivalent due to a surgica l procedure
or new acute event and has previously had a
prescription for the drug or its pharmaceutical
equivalent within the past year.
When determining whether a patient was previously issued a
prescription for a drug or its pharmaceutical equivalent, th e
practitioner shall consult with the patient and review the medical
record and prescription monitoring information of the patient;
29. "Isomer" means the optical isomer, except as used in
subsections C and F of Section 2-204 of this title and paragraph 4
of subsection A of Section 2-206 of this title. As used in
subsections C and F of Section 2-204 of this title, isomer means the
optical, positional or geometric isomer. As used in paragraph 4 of
Req. No. 8538 Page 14 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
subsection A of Section 2-206 of this title, the term isomer means
the optical or geometric isomer;
21. 30. "Laboratory" means a laboratory approved by the
Director as proper to be entrusted with the custody of controlled
dangerous substances and the use of controlled dangerous substances
for scientific and medical purposes and for purposes of instruction;
22. 31. "Manufacture" means the production, preparation,
propagation, compounding or processing of a controlled dangerous
substance, either directly or indirectly by extraction from
substances of natural or synthetic origin, or independently by means
of chemical synthesis or by a combination of extraction and chemical
synthesis. "Manufacturer" includes any person who packages,
repackages or labels any container of any controlled dangerous
substance, except practitioners who dispense or compound
prescription orders for delivery to the ultimate consumer;
23. 32. "Marijuana" means all parts of the plant Cannabis
sativa L., whether growing or not; the seeds thereof; the resin
extracted from any part of such plant; and every compound,
manufacture, salt, derivative, mixture or preparation of such plant,
its seeds or resin, but shall not include:
a. the mature stalks of such plant or fiber produced from
such stalks,
Req. No. 8538 Page 15 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
b. oil or cake made from the seeds of such plant,
including cannabidiol derived from the seeds of the
marijuana plant,
c. any other compound, manufacture, salt, derivative,
mixture or preparation of such mature stalks (except
the resin extracted therefrom), including cannabidiol
derived from mature stalks, fiber, oil or cake,
d. the sterilized seed of such plant which is incapable
of germination,
e. for any person participating in a clinical trial to
administer cannabidiol for the treatment of severe
forms of epilepsy pursuant to Section 2-802 of this
title, a drug or substance approved by the federal
Food and Drug Administration for use by those
participants,
f. for any person or the parents, legal guardians or
caretakers of the person who have received a written
certification from a physician licensed in this state
that the person has been diagnosed by a physician as
having Lennox-Gastaut syndrome, Dravet syndrome, also
known as severe myoclonic epilepsy of infancy, or any
other severe form of epilepsy that is not adequately
treated by traditional medical therapies, spasticity
due to multiple sclerosis or due to paraplegia,
Req. No. 8538 Page 16 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
intractable nausea and vomiting, appetite stimulation
with chronic wasting diseases, the substance
cannabidiol, a nonpsychoactive cannabinoid, found in
the plant Cannabis sativa L. or any other preparation
thereof, that has a tetrahydrocannabinol concentration
not more than three-tenths of one percent (0.3%) and
that is delivered to the patient in the form of a
liquid,
g. any federal Food-and-Drug-Administration-approved drug
or substance, or
h. industrial hemp, from the plant Cannabis sativa L. and
any part of such plant, whether growing or not, with a
delta-9 tetrahydrocannabinol concentration not more
than three-tenths of one percent (0.3%) on a dry-
weight basis which shall only be grown pursuant to the
Oklahoma Industrial Hemp Program and may be shipped
intrastate and interstate;
24. 33. "Medical purpose" means an intention to utilize a
controlled dangerous substance for physical or mental treatment, for
diagnosis, or for the prevention of a disease condition not in
violation of any state or federal law and not for the purpose of
satisfying physiological or psychological dependence or other abuse;
25. 34. "Mid-level practitioner" means an Advanced Practice
Registered Nurse as defined and within parameters specified in
Req. No. 8538 Page 17 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
animal euthanasia technician as defined in Section 698.2 of Title 59
of the Oklahoma Statutes, or an animal control officer registered by
the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
under subsection B of Section 2-301 of this title within the
parameters of such officer's duties under Sections 501 through 508
of Title 4 of the Oklahoma Statutes;
26. 35. "Narcotic drug" means any of the following, whether
produced directly or indirectly by extraction from substances of
vegetable origin, or independently by means of chemical synthesis,
or by a combination of extraction and chemical synthesis:
a. opium, coca leaves and opiates,
b. a compound, manufacture, salt, derivative or
preparation of opium, coca leaves or opiates,
c. cocaine, its salts, optical and geometric isomers, and
salts of isomers,
d. ecgonine, its derivatives, their salts, isomers and
salts of isomers, and
e. a substance, and any compound, manufacture, salt,
derivative or preparation thereof, which is chemically
identical with any of the substances referred to in
subparagraphs a through d of this paragraph, except
that the words narcotic drug as used in Section 2-101
et seq. of this title shall not include decocainized
Req. No. 8538 Page 18 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
coca leaves or extracts of coca leaves, which extracts
do not contain cocaine or ecgonine;
27. 36. "Opiate" or "opioid" means any Schedule II, III, IV or
V substance having an addiction-forming or addiction-sustaining
liability similar to morphine or being capable of conversion into a
drug having such addiction-forming or addiction-sustaining
liability. The terms do not include, unless specifically designated
as controlled under the Uniform Controlled Dangerous Substances Act,
the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its
salts (dextromethorphan). The terms do include the racemic and
levorotatory forms;
28. 37. "Opium poppy" means the plant of the species Papaver
somniferum L., except the seeds thereof;
38. "Palliative care" means a specialized medical service for
people of any age and at any stage of a serious illness or life-
altering medical event that focuses on navigating co mplex medical
decisions while providing patient autonomy and access to
information. Utilizing a holistic and interdisciplinary team
approach, palliative care addresses physical, intellectual,
emotional, social, and spiritual needs. Palliative care may be
provided in the inpatient, outpatient, or home care setting and
strives to improve quality of lif e for both the patient and the
family;
Req. No. 8538 Page 19 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
39. "Patient-provider agreement" means a written contract or
agreement that is executed between a practitioner and a patien t,
prior to the commencement of treatment for chronic pain using an
opioid drug as a means to:
a. explain the possible risk of development of physical
or psychological dependence in the patient and prevent
the possible development of addiction,
b. document the understanding of both the practitioner
and the patient regarding the patient-provider
agreement of the patient,
c. establish the rights of the patient in association
with treatment and the obligations of the patient in
relation to the responsible use, discontinuation of
use, and storage of opioid drugs, including any
restrictions on the refill of prescriptions or the
acceptance of opioid prescriptions from practitioners,
d. identify the specific medications and other modes of
treatment, including physical therapy or exercise,
relaxation or psychological counseling, that are
included as a part of the patient-provider agreement,
e. specify the measures the practitioner may employ to
monitor the compliance of the patient including, but
not limited to, rand om specimen screens and pill
counts, and
Req. No. 8538 Page 20 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
f. delineate the process for terminating the agreement,
including the consequences if the practitioner has
reason to believe that the patient is not complying
with the terms of the agreement. Compliance with the
"consent items" shall constitute a valid, informed
consent for opioid therapy. The practitioner shall be
held harmless from civil litigation for failure to
treat pain if the event occurs because of nonadherence
by the patient with any of the provisions of the
patient-provider agreement;
29. 40. "Peace officer" means a police officer, sheriff, deputy
sheriff, district attorney's investigator, investigator from the
Office of the Attorney General, or any other person elected or
appointed by law to enforce any of the criminal laws of this state
or of the United States;
30. 41. "Person" means an individual, corporation, government
or governmental subdivision or agency, business trust, estate,
trust, partnership or association, or any other legal entity.
Person includes all beneficial owners of a legal entity where
ownership disclosure is a condition or requirement of licensing or
registration;
31. 42. "Poppy straw" means all parts, except the seeds, of the
opium poppy, after mowing;
Req. No. 8538 Page 21 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
32. 43. "Practitioner" means:
a. (1) a medical doctor or osteopathic physician,
(2) a dentist,
(3) a podiatrist,
(4) an optometrist,
(5) a veterinarian,
(6) a physician assistant or Advanced Practice
Registered Nurse under the supervision of a
licensed medical doctor or osteopathic physician,
(7) a scientific investigator, or
(8) any other person,
licensed, registered or otherwise permitted to
prescribe, distribute, dispense, conduct research with
respect to, use for scientific purposes or administer
a controlled dangerous substance in the course of
professional practice or research in this state, or
b. a pharmacy, hospital, laboratory or other institution
licensed, registered or otherwise permitted to
distribute, dispense, conduct research with respect
to, use for scientific purposes or administer a
controlled dangerous substance in the course of
professional practice or research in this state;
Req. No. 8538 Page 22 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
33. 44. "Production" includes the manufacture, planting,
cultivation, growing or harvesting of a controlled dangerous
substance;
45. "Serious illness" means a medical illness or physical
injury or condition that substantially affects quality of life for
more than a short period of time. Serious illness includes, but is
not limited to, Alzheimer's disease or related dementias, lung
disease, cancer, heart failure, renal failure, liver failure, or
chronic, unremitting, or intractable pain such as neuropathic pain;
34. 46. "State" means the State of Oklahoma or any other state
of the United States;
47. "Straw person" or "straw party" also know as a "front"
means a third party who:
a. is put up in name only to take part in a transaction
or otherwise is a nominal party to a transaction with
no actual control,
b. acts on behalf of another person to obtain title to
property and executes documents and instruments the
principal may direct respecting property, or
c. purchases property for anot her for the purpose of
concealing the identity of the real purchaser or to
accomplish some purpose otherwise in violation of
Oklahoma statutes;
Req. No. 8538 Page 23 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
48. "Surgical procedure" means a procedure that is performed
for the purpose of structurally altering the human body by incision
or destruction of tissues as part of the practice of medicine. This
term includes the diagnostic or therapeutic treatment of conditions
or disease processes by use of instruments such as lasers,
ultrasound, ionizing, radiation, scalpels, probes, or needles that
cause localized alteration or transportation of live human tissue by
cutting, burning, vaporizing, freezing, suturing, probing, or
manipulating by closed reduction for major dislocations or
fractures, or otherwise altering by any mechanical, thermal, light-
based, electromagnetic, or chemical means;
49. a. "Synthetic controlled substance" means a substance:
(1) the chemical structure of which is substantially
similar to the chemical structure of a controlled
dangerous substance in Schedule I or II,
(2) which has a stimulant, depressant, or
hallucinogenic effect on the cent ral nervous
system that is substantially similar to or
greater than the stimulant, depressant, or
hallucinogenic effect on the central nervous
system of a controlled dangerous substance in
Schedule I or II, or
(3) with respect to a particular person, which such
person represents or intends to have a stimulant,
Req. No. 8538 Page 24 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
depressant, or hallucinogenic effect on the
central nervous system that is substantially
similar to or greater than the stimulant,
depressant, or hallucinogenic effect on the
central nervous system of a controlled dangerous
substance in Schedule I or II.
b. The designation of gamma butyrolactone or any other
chemical as a precursor, pursuant to Section 2-322 of
this title, does not preclude a finding pursuant to
subparagraph a of this paragraph that the chemical is
a synthetic controlled substance.
c. "Synthetic controlled substance" does not include:
(1) a controlled dangerous substance,
(2) any substance for which there is an approved new
drug application,
(3) with respect to a particular person any
substance, if an exemption is in effect for
investigational use, for that person under the
provisions of Section 505 of the Federal Food,
Drug and Cosmetic Act, Title 21 of the United
States Code, Section 355, to the extent conduct
with respect to such subst ance is pursuant to
such exemption, or
Req. No. 8538 Page 25 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(4) any substance to the extent not intended for
human consumption before such an exemption takes
effect with respect to that substance.
d. Prima facie evidence that a substance containing
salvia divinorum has been en hanced, concentrated or
chemically or physically altered shall give rise to a
rebuttable presumption that the substance is a
synthetic controlled substance;
50. "Tetrahydrocannabinols" means all substances that have been
chemically synthesized to emulate the tetrahydrocannabinols of
marijuana, specificall y including any tetrahydrocannabinols derived
from industrial hemp; and
35. 51. "Ultimate user" means a person who lawfully possesses a
controlled dangerous substance for the person's own use or for the
use of a member of the person's household or for administration to
an animal owned by the person or by a member of the person's
household;
36. "Drug paraphernalia" means all equipment, products and
materials of any kind which are used, intended for use, or fashioned
specifically for use in planting, propagating, cultivating, growing,
harvesting, manufacturing, comp ounding, converting, producing,
processing, preparing, testing, analyzing, packaging, repackaging,
storing, containing, concealing, injecting, ingesting, inhaling or
otherwise introducing into the human body, a controlled dangerous
Req. No. 8538 Page 26 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
substance in violation o f the Uniform Controlled Dangerous
Substances Act including, but not limited to:
a. kits used, intended for use, or fashioned specifically
for use in planting, propagating, cultivating, growing
or harvesting of any species of plant which is a
controlled dangerous substance or from which a
controlled dangerous substance can be derived,
b. kits used, intended for use, or fashioned specifically
for use in manufacturing, compounding, converting,
producing, processing or preparing controlled
dangerous substances ,
c. isomerization devices used, intended for use, or
fashioned specifically for use in increasing the
potency of any species of plant which is a controlled
dangerous substance,
d. testing equipment used, intended for use, or fashioned
specifically for use in identifying, or in analyzing
the strength, effectiveness or purity of controlled
dangerous substances,
e. scales and balances used, intended for use, or
fashioned specifically for use in weighing or
measuring controlled dangerous substances,
f. diluents and adulterants, such as quinine
hydrochloride, mannitol, mannite, dextrose and
Req. No. 8538 Page 27 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
lactose, used, intended for use, or fashioned
specifically for use in cutting controlled dangerous
substances,
g. separation gins and sifters used, intended for use, or
fashioned specifically for use in removing twigs and
seeds from, or in otherwise cleaning or refining,
marijuana,
h. blenders, bowls, containers, spoons and mixing devices
used, intended for use, or fashioned specifically for
use in compounding controlled dange rous substances,
i. capsules, balloons, envelopes and other containers
used, intended for use, or fashioned specifically for
use in packaging small quantities of controlled
dangerous substances,
j. containers and other objects used, intended for use,
or fashioned specifically for use in parenterally
injecting controlled dangerous substances into the
human body,
k. hypodermic syringes, needles and other objects used,
intended for use, or fashioned specifically for use in
parenterally injecting controlled dan gerous substances
into the human body,
l. objects used, intended for use, or fashioned
specifically for use in ingesting, inhaling or
Req. No. 8538 Page 28 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
otherwise introducing marijuana, cocaine, hashish or
hashish oil into the human body, such as:
(1) metal, wooden, acrylic, glass, stone, plastic or
ceramic pipes with or without screens, permanent
screens, hashish heads or punctured metal bowls,
(2) water pipes,
(3) carburetion tubes and devices,
(4) smoking and carburetion masks,
(5) roach clips, meaning objects used to hold burning
material, such as a marijuana cigarette, that has
become too small or too short to be held in the
hand,
(6) miniature cocaine spoons and cocaine vials,
(7) chamber pipes,
(8) carburetor pipes,
(9) electric pipes,
(10) air-driven pipes,
(11) chillums,
(12) bongs, or
(13) ice pipes or chillers,
m. all hidden or novelty pipes, and
n. any pipe that has a tobacco bowl or chamber of less
than one-half (1/2) inch in diameter in which there is
any detectable residue of any controlled dangerous
Req. No. 8538 Page 29 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
substance as defined in this section or any other
substances not legal for possession or use;
provided, however, the term drug paraphernalia shall not include
separation gins intended for use in preparing tea or spice, clamps
used for constructing electrical equ ipment, water pipes designed for
ornamentation in which no detectable amount of an illegal substance
is found or pipes designed and used solely for smoking tobacco,
traditional pipes of an American Indian tribal religious ceremony,
antique pipes that ar e thirty (30) years of age or older, or drug
testing strips possessed by a person for purposes of determining the
presence of fentanyl or a fentanyl-related compound;
37. a. "Synthetic controlled substance" means a substance:
(1) the chemical structure of which is substantially
similar to the chemical structure of a controlled
dangerous substance in Schedule I or II,
(2) which has a stimulant, depressant, or
hallucinogenic effect on the cent ral nervous
system that is substantially similar to or
greater than the stimulant, depressant or
hallucinogenic effect on the central nervous
system of a controlled dangerous substance in
Schedule I or II, or
(3) with respect to a particular person, which such
person represents or intends to have a stimulant,
Req. No. 8538 Page 30 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
depressant, or hallucinogenic effect on the
central nervous system that is substantially
similar to or greater than the stimulant,
depressant, or hallucinogenic effect on the
central nervous system of a controlled dangerous
substance in Schedule I or II.
b. The designation of gamma butyrolactone or any other
chemical as a precursor, pursuant to Section 2-322 of
this title, does not preclude a finding pursuant to
subparagraph a of this paragraph that the chemical is
a synthetic controlled substance.
c. "Synthetic controlled substance" does not include:
(1) a controlled dangerous substance,
(2) any substance for which there is an approved new
drug application,
(3) with respect to a particular person any
substance, if an exemption is in effect for
investigational use, for that person under the
provisions of Section 505 of the Federal Food,
Drug and Cosmetic Act, Title 21 of the United
States Code, Section 355, to the extent conduct
with respect to such subst ance is pursuant to
such exemption, or
Req. No. 8538 Page 31 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(4) any substance to the extent not intended for
human consumption before such an exemption takes
effect with respect to that substance.
d. Prima facie evidence that a substance containing
salvia divinorum has been en hanced, concentrated or
chemically or physically altered shall give rise to a
rebuttable presumption that the substance is a
synthetic controlled substance;
38. "Tetrahydrocannabinols" means all substances that have been
chemically synthesized to emulate the tetrahydrocannabinols of
marijuana, specifically including any tetrahydrocannabinols derived
from industrial hemp;
39. "Isomer" means the optical isomer, except as used in
subsections C and F of Section 2-204 of this title and paragraph 4
of subsection A of Section 2-206 of this title. As used in
subsections C and F of Section 2-204 of this title, isomer means the
optical, positional or geometric isomer. As used in paragraph 4 of
subsection A of Section 2-206 of this title, the term isomer means
the optical or geometric isomer;
40. "Hazardous materials" means materials, whether solid,
liquid or gas, which are toxic to human, animal, aquatic or plant
life, and the disposal of which materials is controlled by state or
federal guidelines;
Req. No. 8538 Page 32 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
41. "Anhydrous ammonia" means any substance that exhibits
cryogenic evaporative behavior and tests positive for ammonia;
42. "Acute pain" means pain, whether resulting from disease,
accidental or intentional trauma or other cause, that the
practitioner reasonably expects to last only a short period of time.
Acute pain does not include chronic pain, pain being treated as part
of cancer care, hospice or other end-of-life care, or pain being
treated as part of palliative care;
43. "Chronic pain" means pain that persists beyond the usual
course of an acute disease or healing of an injury. Chronic pain
may or may not be associated with an acute or chronic pathologic
process that causes continuous or intermittent pain over months or
years;
44. "Initial prescription" means a prescription issued to a
patient who:
a. has never previously been issued a prescription for
the drug or its pharmaceutical equivalent in the past
year, or
b. requires a prescription for the drug or its
pharmaceutical equivalent due to a surgica l procedure
or new acute event and has previously had a
prescription for the drug or its pharmaceutical
equivalent within the past year.
Req. No. 8538 Page 33 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
When determining whether a patient was previously issued a
prescription for a drug or its pharmaceutical equivalent, th e
practitioner shall consult with the patient and review the medical
record and prescription monitoring information of the patient;
45. "Patient-provider agreement" means a written contract or
agreement that is executed between a practitioner and a patien t,
prior to the commencement of treatment for chronic pain using an
opioid drug as a means to:
a. explain the possible risk of development of physical
or psychological dependence in the patient and prevent
the possible development of addiction,
b. document the understanding of both the practitioner
and the patient regarding the patient-provider
agreement of the patient,
c. establish the rights of the patient in association
with treatment and the obligations of the patient in
relation to the responsible use, discontinuation of
use, and storage of opioid drugs, including any
restrictions on the refill of prescriptions or the
acceptance of opioid prescriptions from practitioners,
d. identify the specific medications and other modes of
treatment, including physical therapy or exercise,
relaxation or psychological counseling, that are
included as a part of the patient-provider agreement,
Req. No. 8538 Page 34 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
e. specify the measures the practitioner may employ to
monitor the compliance of the patient including, but
not limited to, rand om specimen screens and pill
counts, and
f. delineate the process for terminating the agreement,
including the consequences if the practitioner has
reason to believe that the patient is not complying
with the terms of the agreement. Compliance with the
"consent items" shall constitute a valid, informed
consent for opioid therapy. The practitioner shall be
held harmless from civil litigation for failure to
treat pain if the event occurs because of nonadherence
by the patient with any of the provisions of the
patient-provider agreement;
46. "Serious illness" means a medical illness or physical
injury or condition that substantially affects quality of life for
more than a short period of time. Serious illness includes, but is
not limited to, Alzheimer's disease or related dementias, lung
disease, cancer, heart failure, renal failure, liver failure or
chronic, unremitting or intractable pain such as neuropathic pain;
and
47. "Surgical procedure" means a procedure that is performed
for the purpose of structurally altering the human body by incision
or destruction of tissues as part of the practice of medicine. This
Req. No. 8538 Page 35 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
term includes the diagnostic or therapeutic treatment of conditions
or disease processes by use of instruments such as lasers,
ultrasound, ionizing, radiation, scalpels, probes or needles that
cause localized alteration or transportation of live human tissue by
cutting, burning, vaporizing, freezing, suturing, probing or
manipulating by closed reduction for major dislocations or
fractures, or otherwise altering by any mechanical, thermal, light-
based, electromagnetic or chemical means.
SECTION 2. AMENDATORY 63 O.S. 2021, Section 2-305, as
amended by Section 2, Chapter 176, O.S.L. 2023 (63 O.S. Sup p. 2023,
Section 2-305), is amended to read as follows:
Section 2-305. A. In addition to any other remedies provid ed
for by law, the Director shall issue a writt en order to be served on
the parties before annulling, conditioning, suspending or revoking
any registration that the Director has reason to believe is
operating inconsistent with any provision of Section 2 -303 or 2-304
of this title or otherwise, where there has been a violation of any
federal law, any rule or regulati on of the Drug Enforcement
Administration, any provision of the Uniform Controlled Dangerous
Substances Act, or any rules or regulations of the Oklahoma State
Bureau of Narcotics and Dangerous Drugs Control. The provisions of
this subsection shall not apply to a violation of federal law
regarding marijuana or any rul e or regulation of the Drug
Enforcement Administration regarding mar ijuana.
Req. No. 8538 Page 36 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
B. The written order shall state with specifici ty the nature of
the violation or basis for the action. The Director may impose any
disciplinary action authorized by the Uniform C ontrolled Dangerous
Substances Act or rules of the Bureau including, but not limited to,
the assessment of monetary pena lties.
C. Any written order issued pursuant to the provisions of this
section shall become a final order unless the registrant requests an
administrative hearing in ac cordance with the rules and regulations
promulgated by the Director within thirty (30) days of issuance.
Upon such request, the Director shall promptly initiate
administrative proceedings and serve formal notice of said
proceedings pursuant to Section 309 of Title 75 of the Oklahoma
Statutes. Nothing in this section shall be construed so as to
require an individual proceeding for the denial of a new application
for registration.
D. The Director may authorize the Deputy Director or the
general counsel of the Bureau to initiate any individual proceedings
under this title. Nothing in this section shall be construed so as
to delegate the authority of the Director to issue a fina l agency
order of an individual proceeding adverse to a party. If a party
fails to request an individual proc eeding in a timely manner, the
written order as issued shall be deem ed adopted as the final order
by the Director.
Req. No. 8538 Page 37 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
E. 1. All proceedings shall be conducted in accordance with
the Administrative Procedures Act and the rules and regulations of
the Bureau without regard to any criminal prosecution or ot her
proceeding. Proceedings to refuse renewal, revoke, or suspend a
registration shall not abate the existing re gistration which shall
remain in effect pending the outcome of the administrativ e
proceedings.
This abatement shall not apply wh en the Director finds there is
an imminent danger to the public health or safet y requiring an
immediate suspension. Registrants subject to administrative action
shall be required to mai ntain the registration as if it is still in
effect, including the annual sub mission of a renewal applicati on and
associated fee.
2. The Director may delegate to an administrative hearing
officer the authority to conduct hear ings and recommend action for
final agency orders in accordance with the rules and regulations of
the Bureau.
F. The Director may issue an order immediately suspending a
registration, without n otice or a hearing, when he or she the
Director finds there is imminent dan ger to the public health o r
safety which warrants this action. The suspension shall continue in
effect until the conclusion of any administrative proceedings,
including judicial review thereof, unless sooner withdrawn by the
Director or dissolved by a cou rt of competent jurisdicti on. The
Req. No. 8538 Page 38 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
order shall state the existence of an emergency requiring action be
taken that the Director deems necessary to meet the emergency. Such
action may include, bu t is not limited to, ordering the registrant
to immediately cease and desist operations . The order shall be
effective immediately upon issuance . Any person to whom th e order
is directed shall comply immediately with the provision s of the
order. The Director may assess a penalty not to exceed Ten Thousand
Dollars ($10,000.00) per day of non compliance with the order. In
assessing such a penalty, the Director shall consid er the
seriousness of the violation and any efforts to comply with
applicable requirements. Upon application to the Director, the
registrant shall be offered a hearing withi n thirty (30) days of the
issuance of the order.
G. 1. In lieu of, or in addition to any other remedies
available to the Director, if a find ing is made that a regist rant
has committed any act in violation of federal law relating to any
controlled dangerous substance, any provision of the Uniform
Controlled Dangerous Substances Act , or any rules of the Bureau, the
Director is hereby authorized to assess an administrati ve penalty
not to exceed Five Thousand Dollars ($5,000.00) per day for each
such act. The provisions of this subsection shall not apply to
violations of subsection G of Secti on 2-309D of this title. Nothing
in this section shall be construed so as to per mit the Director of
Req. No. 8538 Page 39 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
the Bureau to assess administrative fines f or violations of the
provisions of subsection G of Section 2-309D of this title.
2. If a judge of competent jur isdiction finds probable cause
that a registrant has possessed, transferred, sol d, or offered for
sale any controlled dangerous substance in violation of the Uniform
Controlled Dangerous Substances Act, any controlled dangerous
substance in Schedule I of Section 2-204 of this title, and any
controlled dangerous substance in Schedules II, III, IV, and V that
is not in properly labeled containers in accordance with the Uniform
Controlled Dangerous Substances Act then in the possession of the
registrant, shall be deemed contraband and shall be seized and
summarily forfeited pursuant to Se ction 2-505 of this title.
Samples shall be retained of all con trolled dangerous substanc es
seized in accordance with Section 2-508 of this title as required.
The Director is authorized to assess an eradication or destruction
fine not to exceed Fifty Thousand Dollars ($50,000.00) against the
registrant.
H. Upon an annulment, revocation, or de nial of a registration,
the Director may prohibit the registrant or ap plicant from
reapplying for registration for a period up to five (5) years
following the date o f the final order. The length of any
prohibition shall not be us ed as grounds to contest t he validity of
the annulment, revocation, or denial of a registration.
Req. No. 8538 Page 40 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SECTION 3. AMENDATORY 63 O.S. 2021, Section 2 -309, as
amended by Section 2, Chapter 304, O.S.L. 2023 (63 O.S. Supp. 2023,
Section 2-309), is amended to read as f ollows:
Section 2-309. A. 1. Except for dosages medically required
for a period not to exceed forty-eight (48) hours which are
administered by or on direction of a practitioner, other than a
pharmacist, or medication dispensed directly by a practitioner,
other than a pharmac ist, to an ultimate user, no controlled
dangerous substance included in Sc hedule II, which is a prescription
drug as determined und er regulation promulgated by the Board of
Pharmacy, shall be dispensed without an electronic prescription of a
practitioner; provided, that in emergency situations, as prescribed
by the Board of Phar macy by regulation, such drug may be dispensed
upon oral prescription reduced promptly to writing and filed by the
pharmacist in a manner to be prescribed by rules and regulations of
the Director of the Oklahoma State Bureau of Narcotics and Dangerous
Drugs Control.
2. Electronic prescribing shall be utilized f or Schedules II,
III, IV and V, subject to the requirements set forth i n 21 CFR,
Section 1311 et seq.
3. An electronic presc ription with electronic signature may
serve as an original prescription, s ubject to the requirements set
forth in 21 CFR, Section 1 311 et seq.
Req. No. 8538 Page 41 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
4. Prescriptions shall be retained in conformity with the
requirements of this section and Section 2-307 of this title. No
prescription for a Schedule II substance may be refilled.
5. The electronic prescription requirement provided for in t his
section shall not apply to prescriptions for controlled dangerous
substances issued by any of the following:
a. a person licensed to practice veterinary medicine,
b. a practitioner who experience s temporary technological
or electrical failure or other extenuating
circumstance that prevents the prescription from being
transmitted electronically; provided, however, that
the practitioner documents the reason for this
exception in the medical record o f the patient,
c. a practitioner, other than a pharmacist , who dispenses
directly to an ultimate user,
d. a practitioner who ord ers a controlled dangerous
substance to be administere d through an on-site
pharmacy in:
(1) a hospital as defined in Section 1 -701 of this
title,
(2) a nursing facility as defined in Se ction 1-1902
of this title,
(3) a hospice inpatient facility as defined in
Section 1-860.2 of this title,
Req. No. 8538 Page 42 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(4) an outpatient dialysis facility,
(5) a continuum of care facility as defined in
Section 1-890.2 of this title, or
(6) a penal institution listed i n Section 509 of
Title 57 of the Oklahoma Statutes,
e. a practitioner who orders a controlled dangerous
substance to be admin istered through a hospice program
including but not limited to a hospice program that
provides hospice services in the private residence of
a patient or in a long-term care facility where the
patient resides. As used in this subparagraph,
"hospice program" has the same meaning as provided by
Section 1-860.2 of this title,
f. a practitioner who writes a prescription to be
dispensed by a pharmacy located on federal property,
provided the practitioner documents the reason for
this exception in the medic al record of the patient,
or
g. a practitioner that has received a waiv er or extension
from his or her licensing board.
6. Electronic prescriptions shall not may be utilized under the
following circumstances:
Req. No. 8538 Page 43 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
a. compound compounded prescriptions containing two or
more commercially available products or two or more
active pharmaceutical ingredients,
b. compounded infusion prescriptions containing two or
more commercially available products or two or mo re
active pharmaceutical ingredient s, or
c. prescriptions issued under app roved research
protocols, or
d. if the practitioner determines that an electronic
prescription cannot be issued in a timely manner and
the condition of the patient is at risk .
7. A pharmacist who receives a written, ora l or facsimile
prescription shall no t be required to verify that the prescription
falls under one of the exceptions provided for in paragraph 6 of
this subsection. Pharmacists may cont inue to dispense medications
from otherwise valid written, oral or facs imile prescriptions that
are consistent with the provisions of this section.
8. Practitioners sha ll indicate in the health record of a
patient that an exception to the electronic presc ription requirement
was utilized.
9. All prescriptions issued pursuant to paragraphs 5 and 6 of
this subsection shall be issued on an official prescription form
provided by the Oklahoma State Bureau of Narcotics and Dangerous
Drugs Control if not issued electronically .
Req. No. 8538 Page 44 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
10. a. Effective January 1, 2020, practitioners shall
register with the Oklahoma Stat e Bureau of Narcotics
and Dangerous Drugs Control in order to be issued
official prescription forms. Such registration shall
include, but not be limited to, the primary address
and the address of each place of business to be
imprinted on official prescrip tion forms. Any change
to a registered practitioner's registered address
shall be promptly reported to the practitioner's
licensing board and the Bureau by the practitioner in
a manner approved by the Bureau.
b. A practitioner's registration shall be with out fee and
subject to approval by the Bureau. Such registration
shall be valid for a period of two (2) years and may
be denied, suspended or revoked by the Bureau upon a
finding by the Bureau or licensing board that the
registered practitioner has had an y license to
practice a medical pro fession revoked or suspended by
any state or federal agency.
c. Where the Bureau has revoked the registration of a
registered practitioner, the Bureau may revoke or
cancel any official prescription forms in the
possession of the registered practitioner. A ny
revocation or any suspension shall require the
Req. No. 8538 Page 45 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
registered practitioner to return all unused official
prescription forms to the Bureau within fiftee n (15)
calendar days after the date of the written
notification.
d. A practitioner that has had any licens e to practice
terminated, revoked or suspended by a state or federal
agency may, upon restoration of such license or
certificate, register to be issue d official
prescription forms.
11. a. Except as provided in subparagrap h f of this
paragraph, the Bureau shall issue official Official
prescription forms free of charge only to registered
practitioners in this state. Such forms shall not be
transferable. The numb er of official prescription
forms issued to a registered shall be purchased at the
expense of the practitioner at any time shall be at
the discretion of or the employer of the practitioner
from a list of vendors approved by the Bureau.
b. Official prescription forms issued to a registered
practitioner shall be imprinted only with the primary
address and may include other addresses listed on the
registration of the practitioner to identify the place
of origin. Such prescriptions shall be sent only to
the primary address of the registered practitioner.
Req. No. 8538 Page 46 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
c. Official prescription forms issued to of a registered
practitioner shall be used o nly by the practitioner to
whom they are issued designated on the official
prescription form.
d. The Bureau may revoke or cancel official prescription
forms in possession of registered practitioners when
the license of such practitioner i s suspended,
terminated or revoked.
e. Official prescription forms of registered
practitioners who are deceased or who no lon ger
prescribe shall be returned to the Bureau at a
designated address. If the registered practitioner is
deceased, it is the resp onsibility of the registered
practitioner's estate or lawful designee to return
such forms.
f. The Bureau may issue official p rescription forms to
employees or agents of the Bureau and other government
agencies for the purpose of preventing, identifying,
investigating and prosecuting unacceptable or illegal
practices by providers and other person s and assisting
in the recovery of overpayments under any program
operated by the state or paid for with state funds.
Such prescription forms shall be issued for this
purpose only to individuals who are authorized to
Req. No. 8538 Page 47 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
conduct investigations on behalf of th e Bureau or
other government agenc ies as part of their official
duties. Individuals and agencies receiving such
prescription forms for this purpose shall provide
appropriate assurances to the Bureau that adequate
safeguards and security measures are in pl ace to
prevent the use of such pre scription forms for
anything other than official government purposes.
12. a. Adequate safeguards and security measures shall be
undertaken by registered practitioners holding
official prescription forms to assure against t he
loss, destruction, theft or un authorized use of the
forms. Registered practitioners shall maintain a
sufficient but not excessive supply of such forms in
reserve.
b. Registered practitioners shall immediately notify the
Bureau, in a manner designated b y the Bureau, upon
their knowledge of the loss, destruction, theft or
unauthorized use of any official prescription forms
issued to them, as well as the failure to receive
official prescription forms within a reasonable time
after ordering them from the Bu reau.
c. Registered practitioners shall immediately notify the
Bureau upon their knowledge of any diversion or
Req. No. 8538 Page 48 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
suspected diversion of drugs pursuant to the los s,
theft or unauthorized use of prescriptions.
B. 1. Except for dosages medically required for a period not
to exceed seventy-two (72) hours which are administered by or on
direction of a practitioner, other than a pharmacist, or medication
dispensed directly by a practiti oner, other than a pharmacist, to an
ultimate user, no controlled dangerous su bstance included in
Schedule III or IV, which is a prescription drug as determined under
regulation promulgated by the Board of Pharmacy, shall be dispensed
without an electronic prescription.
2. Any prescription for a controlled dangerous substance in
Schedule III, IV or V may not be fi lled or refilled more than six
(6) months after the date thereof or be refilled more than five
times after the date of the prescription, unless r enewed by the
practitioner.
C. Whenever it appears to the Director of the Okl ahoma State
Bureau of Narcotics a nd Dangerous Drugs Control that a drug not
considered to be a prescription drug under existing state law or
regulation of the Board of Pharmacy s hould be so considered because
of its abuse potential, the Director shall so a dvise the Board of
Pharmacy and furnish to the Board all available data relevant
thereto.
D. 1. "Prescription", as used in this section, means a
written, oral or electronic ord er by a practitioner to a pharmacist
Req. No. 8538 Page 49 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
for a controlled dangerous substance for a particular patient, which
specifies the date of its issue, and the full name and address of
the patient and, if the controlled dangerous substance is prescribed
for an animal, the species of the animal, the name and quantity of
the controlled dangerous s ubstance prescribed, the directio ns for
use, the name and address of the owner of the animal and, if
written, the signature of the practitioner.
2. "Registered practitioner", as used in this section, means a
licensed practitioner duly registered with the Oklahoma State Bureau
of Narcotics and Dangerous Drugs Control to be issued official
prescription forms.
E. No person shall solicit, dispense, receive or deliver any
controlled dangerous substance through the mail, unless the ultimate
user is personally k nown to the practitioner and circ umstances
clearly indicate such method of delivery is in the best interest of
the health and welfare of the ultimate user.
SECTION 4. AMENDATORY 63 O.S. 2021, Section 2 -406, as
amended by Section 2, Chapter 235, O.S.L. 2023 (63 O.S. Supp. 2023,
Section 2-406), is amended to read as follows:
Section 2-406. A. It shall be unlawful for any registrant
person knowingly or intentio nally:
1. To distribute, other than by dispensing or as otherwise
authorized by the Uniform Controlled Dangerous Substances Act , a
controlled dangerous substance cla ssified in Schedules I or II, in
Req. No. 8538 Page 50 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
the course of his or her legitimate business, except purs uant to an
order form as required by Section 2 -308 of this title;
2. To use in the course of t he manufacture or distribution of a
controlled dangerous substance a registration number which is
fictitious, revoked, suspended or issued to another person;
3. To acquire or obtain possession of a controlled dangerous
substance by misrepresentation, fra ud, forgery, deception or
subterfuge;
4. To furnish false or fraudulent material information in, or
omit any material information from, any application, report, or
other document required to be kept or filed unde r the Uniform
Controlled Dangerous Substances Act, or any record required to be
kept by the Uniform Controlled Dangerous Substances Act;
5. To make, distribute, or possess any punch, die, plate,
stone, or other thing designed to print, imprint, or reproduce the
trademark, trade name, or other identifying mark, imprint, or device
of another or any likeness of any of the foregoing upon any drug or
container or labeling thereof so as to render such drug a
counterfeit controlled dangerous substance; and
6. To purchase, or attempt, endeavor, or conspire to obtain or
purchase, any license or registration required to distribute,
possess, prescribe, or manufacture any controlled dangerous
substance on behalf of, or at the request or demand of, any other
person through the use of a straw person or straw party.
Req. No. 8538 Page 51 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
B. Any person who violates this section is gu ilty of a felony
punishable by imprisonment for not more than twenty (20) years or a
fine not more than Two Hundred Fifty Thousand Dollars ($250,000.00),
or both.
C. Any person convicted of a second or subsequent violation of
this section is punishable by a term of imprisonment twice that
otherwise authorized and by twice the fine otherwise authorized.
Convictions for second or subsequent violations of this section
shall not be subject to statutory provisions for suspended
sentences, deferred sentences, o r probation.
D. Any person convicted of any offense described in this
section shall, in addition to any fi ne imposed, pay a special
assessment trauma-care fee of One Hundred Dollars ($100.00) to be
deposited into the Trauma Car e Assistance Revolving Fund created in
Section 1-2530.9 of this title.
SECTION 5. REPEALER 63 O.S. 2021, Section 2-101, as last
amended by Section 10, Chapter 91, O.S.L. 2019, Section 1, Chapter
235, O.S.L. 2023 and Section 1, Chapter 304, O.S.L. 2023, 2-305, as
last amended by Section 4, Chapter 375, O.S.L. 2023, 2-309, as last
amended by Section 1, Chapter 333, O.S.L. 2021 and 2-406 as last
amended by Section 7, Chapter 375 , O.S.L. 2023 (63 O.S. Supp. 2023,
Sections 2-101, 2-305, 2-309 and 2-406), are hereby repealed.
Req. No. 8538 Page 52 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SECTION 6. This act shall become effective November 1, 2024.
59-2-8538 GRS 12/31/23